Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
GROWTH INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/208505
Kind Code:
A1
Abstract:
The present invention relates to a method for producing an insulin-producing cell population or a pancreas β cell population in which Ki67 positive cells are reduced, the method comprising treating a population of endocrine progenitor cells or further differentiated cells with an FGFR1 inhibitor.

Inventors:
YAMAZOE Noriko (26-1 Muraoka-Higashi 2-chome, Fujisawa-sh, Kanagawa 12, 〒2510012, JP)
HIYOSHI Hideyuki (26-1 Muraoka-Higashi 2-chome, Fujisawa-sh, Kanagawa 12, 〒2510012, JP)
MOCHIDA Taisuke (26-1 Muraoka-Higashi 2-chome, Fujisawa-sh, Kanagawa 12, 〒2510012, JP)
ITO Ryo (26-1 Muraoka-Higashi 2-chome, Fujisawa-sh, Kanagawa 12, 〒2510012, JP)
TOYODA Taro (36-1 Yoshida-honmachi, Sakyo-ku, Kyoto-sh, Kyoto 01, 〒6068501, JP)
KIMURA Azuma (36-1 Yoshida-honmachi, Sakyo-ku, Kyoto-sh, Kyoto 01, 〒6068501, JP)
Application Number:
JP2019/017044
Publication Date:
October 31, 2019
Filing Date:
April 22, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KYOTO UNIVERSITY (36-1, Yoshida-honmachi Sakyo-ku, Kyoto-sh, Kyoto 01, 〒6068501, JP)
TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1 Doshomachi 4-chome, Chuo-ku Osaka-sh, Osaka 45, 〒5410045, JP)
International Classes:
C12N5/077
Foreign References:
JP2014519854A2014-08-21
US20050069529A12005-03-31
Other References:
YAMASHITA-SUGAHARA YZUMI ET AL: "An inhibitor of fibroblast growth factor receptor-1 (FGFR1) promotes late-stage terminal differentiation from NGN3+ pancreatic endocrine progenitors.", SCIENTIFIC REPORTS, vol. 6, no. 1, pages 15 - 10, XP055646902, DOI: 10.1038/srep35908
Attorney, Agent or Firm:
OHNO Seiji et al. (OHNO & PARTNERS, Marunouchi Kitaguchi Building 21F 6-5, Marunouchi 1-chome, Chiyoda-k, Tokyo 05, 〒1000005, JP)
Download PDF: